HOLON, Israel, May 25, 2017 /PRNewswire/ --
Compugen Ltd. (NASDAQ: CGEN), a
therapeutic discovery company, today announced that Michal Preminger, PhD, MBA, Executive Director
at Harvard University Office of
Technology Development's Harvard Medical
School site, has been appointed a Director of Compugen by
the Company's Board of Directors.
Dr. Preminger brings to Compugen broad managerial and business
experience focused on the pharma and biotech industries. At Harvard
Office of Technology Development, she has negotiated a multitude of
licensing and strategic alliance agreements with pharmaceutical and
biotechnology companies and supported the launch of many
biotechnology startups.
Prior to joining Harvard in 2005,
Dr. Preminger held a number of senior executive business
development and R&D positions in technology and biotechnology
companies, including at Compugen, where she was a member of the
management team that took the Company public in August 2000. Dr. Preminger is a member of the
board of directors of BioArray Genetics and Israel Brain
Technologies, and a member of the Scientific Advisory Board at
FutuRx (a partnership between Takeda Pharmaceuticals, Johnson &
Johnson and Orbimed Ventures) and Prize4Life.
"The opportunity to join Compugen at its current development
stage is gratifying," said Dr. Preminger. "I look forward to
helping Compugen bring its first-in-class therapeutics pipeline,
originating from its computational target discovery capabilities,
into products for patients not benefitting from currently available
treatments."
Anat Cohen-Dayag, PhD, President
and CEO of Compugen, stated, "We are delighted to welcome Dr.
Preminger to the Company as a member of the Board. We look forward
to benefitting from Dr. Preminger's broad business experience
across the pharma and biotech industries, as we continue to focus
on the various therapeutic and business opportunities presented by
our pipeline and our unique discovery capabilities."
Dr. Preminger holds an undergraduate degree in Medicine from the
Hebrew University of Jerusalem's School
of Medicine, MSc and PhD from the Weizmann Institute of Science,
and an MBA from INSEAD in Fontainebleau, France.
About Compugen
Compugen is a leading therapeutic discovery company whose
mission is to utilize its broadly applicable predictive discovery
infrastructure to discover novel drug targets and develop
first-in-class therapeutics. Our current pipeline consists of early
and preclinical stage immuno-oncology programs based on novel drug
targets discovered internally, primarily immune checkpoint and
myeloid protein target candidates. These programs focus on the
development of first-in-class cancer immunotherapy drugs with the
potential to harness the immune system to provide treatment
solutions in areas of unmet medical need in various cancer types
and patient populations, both as monotherapy and in combination
with other drugs. In addition, our pipeline currently includes a
preclinical fusion protein autoimmune product candidate. Compugen's
business model is based on selectively entering into collaborations
for its novel target candidates and related drug product candidates
at various stages of research and development under revenue-sharing
agreements. The Company is headquartered in Israel, with R&D facilities in
Israel and South San Francisco. At
the US facilities, therapeutic monoclonal antibodies are discovered
and developed against the Company's novel drug target candidates.
For additional information, please visit Compugen's corporate
website at http://www.cgen.com.
Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
terminology such as "will," "may," "expects," "anticipates,"
"believes," "potential," and "intends," and describe opinions about
possible future events. These forward-looking statements involve
known and unknown risks and uncertainties that may cause the actual
results, performance or achievements of Compugen to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Among
these risks: Compugen's business model is substantially dependent
on entering into collaboration agreements with third parties, and
Compugen may not be successful in generating adequate revenues or
commercializing aspects of its business model. Moreover, the
development and commercialization of therapeutic candidates involve
many inherent risks, including failure to progress to clinical
trials or, if they progress to or enter clinical trials, failure to
receive regulatory approval. These and other factors are more fully
discussed in the "Risk Factors" section of Compugen's most recent
Annual Report on Form 20-F as filed with the Securities and
Exchange Commission (SEC) as well as other documents that may be
subsequently filed by Compugen from time to time with the SEC. In
addition, any forward-looking statements represent Compugen's views
only as of the date of this release and should not be relied upon
as representing its views as of any subsequent date. Compugen does
not assume any obligation to update any forward-looking statements
unless required by law.
Company contact:
Susanna Chau
Director, Investor Relations and Corporate Communications
Compugen
Email: susannac@cgen.com
Tel: +1-650-263-7001
SOURCE Compugen Ltd.